Advertisement

Infection

, Volume 43, Issue 6, pp 681–689 | Cite as

High variability among Emergency Departments in 3rd-generation cephalosporins and fluoroquinolones use for community-acquired pneumonia

  • Eric BatardEmail author
  • Nathalie Lecadet
  • Nicolas Goffinet
  • Jean-Benoit Hardouin
  • The CEFPU1 Study Group
  • Didier Lepelletier
  • Gilles Potel
  • Emmanuel Montassier
Original Paper

Abstract

Objective

Fluoroquinolones and 3rd-generation cephalosporins that are prescribed for pneumonia may be avoided and replaced by a penicillin in some cases. We aimed to determine if the proportion of patients treated for pneumonia with a cephalosporin, a fluoroquinolone or both varies among Emergency Departments (EDs), and to estimate the proportion of avoidable prescriptions.

Methods

This was a retrospective study of patients treated for pneumonia in eight French EDs, and subsequently hospitalized in non-ICU wards. Third-generation cephalosporins or respiratory fluoroquinolones were presumed unavoidable if they met both criteria: (1) age ≥65 years or comorbid condition; and (2) allergy or intolerance to penicillin, or failure of penicillin, or previous treatment with penicillin, or for fluoroquinolones only, suspected legionellosis.

Results

We included 832 patients. Thirty-four percent (95 % CI, 31–38 %) of patients were treated with a cephalosporin, a respiratory fluoroquinolone or both (range among EDs 19–44 %). Four EDs were independent risk factors for prescription of a cephalosporin, a fluoroquinolone or both [adjusted OR, 2.27 (1.64–3.15)], as were immune compromise [aOR 2.54 (1.56–4.14)], antibacterial therapy started before arrival in the ED [aOR 3.32 (2.30–4.81)], REA-ICU class III or IV [aOR 1.93 (1.15–3.23)], PSI class V [aOR 1.49 (1.00–2.20)], fluid ressuscitation [aOR 3.98 (2.49–6.43)] and non-invasive ventilation in the ED [aOR, 7.18 (1.7–50.1)]. Treatment with a cephalosporin, a fluoroquinolone or both was avoidable in 67 % (62–73 %) of patients.

Conclusion

Cephalosporins and fluoroquinolones use in pneumonia is highly variable among EDs. The majority of these prescriptions are avoidable. Antibiotic stewardship programs should be implemented to restrict their use in EDs.

Keywords

Community-acquired pneumonia Antibiotic prescription Prudent use Cephalosporins Fluoroquinolones Emergency department 

Notes

Acknowledgments

The authors acknowledge Jacques Choukroun, Philippe Fradin, Christophe Legal, Betty Mazet, Amélie Pichot, Bruno Poujol and Rachid Yousfi for helping local investigators.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval

This study was approved by the ethics committee of Centre Hospitalier Universitaire de Nantes (Number 2014-04-01).

Supplementary material

15010_2015_793_MOESM1_ESM.docx (13 kb)
Supplementary material 1 (DOCX 12 kb)

References

  1. 1.
    Kaier K, Frank U, Hagist C, Conrad A, Meyer E. The impact of antimicrobial drug consumption and alcohol-based hand rub use on the emergence and spread of extended-spectrum beta-lactamase-producing strains: a time-series analysis. J Antimicrob Chemother. 2009;63:609–14.CrossRefPubMedGoogle Scholar
  2. 2.
    Kanafani ZA, Mehio-Sibai A, Araj GF, Kanaan M, Kanj SS. Epidemiology and risk factors for extended-spectrum beta-lactamase-producing organisms: a case control study at a tertiary care center in Lebanon. Am J Infect Control. 2005;33:326–32.CrossRefPubMedGoogle Scholar
  3. 3.
    Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis. 2004;23:163–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Rodriguez-Bano J, Alcala JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med. 2008;168:1897–902.CrossRefPubMedGoogle Scholar
  5. 5.
    Aldeyab MA, Harbarth S, Vernaz N, Kearney MP, Scott MG, Darwish Elhajji FW, et al. The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings. Br J Clin Pharmacol. 2012;74:171–9.PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103–20.CrossRefPubMedGoogle Scholar
  7. 7.
    Paterson DL. “Collateral damage” from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis. 2004;38(Suppl 4):S341–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Roson B, Carratala J, Tubau F, Dorca J, Linares J, Pallares R, et al. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin–clavulanate and ceftriaxone. Microb Drug Resist. 2001;7:85–96.CrossRefPubMedGoogle Scholar
  9. 9.
    Sanchez ME, Gomez J, Gomez Vargas J, Banos V, Ruiz Gomez J, Munoz L, et al. Prospective and comparative study between cefuroxime, ceftriaxone and amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. Rev Esp Quimioter. 1998;11:132–8.PubMedGoogle Scholar
  10. 10.
    Paterson DL, Playford EG. Should third-generation cephalosporins be the empirical treatment of choice for severe community-acquired pneumonia in adults? Med J Aust. 1998;168:344–8.PubMedGoogle Scholar
  11. 11.
    Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al. Guidelines for the management of adult lower respiratory tract infections—full version. Clin Microbiol Infect. 2011;17(Suppl 6):E1–59.CrossRefPubMedGoogle Scholar
  12. 12.
    Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–72.CrossRefPubMedGoogle Scholar
  13. 13.
    Goffinet N, Lecadet N, Cousin M, Peron C, Hardouin JB, Batard E, et al. Increasing use of third-generation cephalosporins for pneumonia in the emergency department: may some prescriptions be avoided? Eur J Clin Microbiol Infect Dis. 2014;33:1095–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Blasi F, Garau J, Medina J, Avila M, McBride K, Ostermann H. Current management of patients hospitalized with community-acquired pneumonia across Europe: outcomes from REACH. Resp Res. 2013;14:44.CrossRefGoogle Scholar
  15. 15.
    Neuman MI, Ting SA, Meydani A, Mansbach JM, Camargo CA Jr. National study of antibiotic use in emergency department visits for pneumonia, 1993 through 2008. Acad Emerg Med. 2012;19:562–8.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Trinh HT, Hoang PH, Cardona-Morrell M, Nguyen HT, Vu DH, Dong PT, et al. Antibiotic therapy for inpatients with community-acquired pneumonia in a developing country. Pharmacoepidemiol Drug Saf. 2014;24:129–36.CrossRefPubMedGoogle Scholar
  17. 17.
    Torres A, Blasi F, Peetermans WE, Viegi G, Welte T. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis. 2014;33:1065–79.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Kohlhammer Y, Raspe H, Marre R, Suttorp N, Welte T, Schafer T, et al. Antibiotic treatment of community acquired pneumonia varies widely across Germany. J Infect. 2007;54:446–53.CrossRefPubMedGoogle Scholar
  19. 19.
    Koller D, Hoffmann F, Maier W, Tholen K, Windt R, Glaeske G. Variation in antibiotic prescriptions: is area deprivation an explanation? Analysis of 1.2 million children in Germany. Infection. 2013;41:121–7.CrossRefPubMedGoogle Scholar
  20. 20.
    SPILF, AFSSAPS. Antibiothérapie par voie générale dans les infections respiratoires basses de l’adulte. Pneumonie aigue communautaire, exacerbations de bronchopneumopathie chronique obstructive 2010. http://ansm.sante.fr/var/ansm_site/storage/original/application/b33b6936699f3fefdd075316c40a0734.pdf. Last access 16 Nov 2014.
  21. 21.
    Sorde R, Falco V, Lowak M, Domingo E, Ferrer A, Burgos J, et al. Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. Arch Intern Med. 2011;171:166–72.CrossRefPubMedGoogle Scholar
  22. 22.
    Matta M, Kerneis S, Day N, Lescat M, Hoi AB, Varon E, et al. Do clinicians consider the results of the BinaxNOW Streptococcus pneumoniae urinary antigen test when adapting antibiotic regimens for pneumonia patients? Clin Microbiol Infect. 2010;16:1389–93.CrossRefPubMedGoogle Scholar
  23. 23.
    Engel MF, van Velzen M, Hoepelman AI, Thijsen S, Oosterheert JJ. Positive urinary antigen tests for Streptococcus pneumoniae in community-acquired pneumonia: a 7-year retrospective evaluation of health care cost and treatment consequences. Eur J Clin Microbiol Infect Dis. 2013;32:485–92.CrossRefPubMedGoogle Scholar
  24. 24.
    Duchene E, Montassier E, Boutoille D, Caillon J, Potel G, Batard E. Why is antimicrobial de-escalation under-prescribed for urinary tract infections? Infection. 2013;41:211–4.CrossRefPubMedGoogle Scholar
  25. 25.
    Khasawneh FA, Karim A, Mahmood T, Ahmed S, Jaffri SF, Tate ME, et al. Antibiotic de-escalation in bacteremic urinary tract infections: potential opportunities and effect on outcome. Infection. 2014;42:829–34.CrossRefPubMedGoogle Scholar
  26. 26.
    Cavalié P, Djeraba A. L’évolution des consommations d’antibiotiques en France entre 2000 et 2013. Paris: ANSM; 2014. http://ansm.sante.fr/S-informer/Actualite/Evolution-des-consommations-d-antibiotiques-en-France-entre-2000-et-2013-nouveau-rapport-d-analyse-de-l-ANSM-Point-d-Information. Last access 16 Nov 2014.
  27. 27.
    Borde JP, Litterst S, Ruhnke M, Feik R, Hubner J, deWith K, et al. Implementing an intensified antibiotic stewardship programme targeting cephalosporin and fluoroquinolone use in a 200-bed community hospital in Germany. Infection. 2015;43:45–50.CrossRefPubMedGoogle Scholar
  28. 28.
    May L, Cosgrove S, L’Archeveque M, Talan DA, Payne P, Jordan J, et al. A call to action for antimicrobial stewardship in the emergency department: approaches and strategies. Ann Emerg Med. 2013;62:69–77.CrossRefPubMedGoogle Scholar
  29. 29.
    Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64 Suppl 3:1–55.Google Scholar
  30. 30.
    Singanayagam A, Chalmers JD. Severity assessment scores to guide empirical use of antibiotics in community acquired pneumonia. Lancet Respir Med. 2013;1:653–62.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Eric Batard
    • 1
    • 2
    Email author
  • Nathalie Lecadet
    • 1
  • Nicolas Goffinet
    • 1
  • Jean-Benoit Hardouin
    • 3
  • The CEFPU1 Study Group
  • Didier Lepelletier
    • 2
    • 4
  • Gilles Potel
    • 1
    • 2
  • Emmanuel Montassier
    • 1
    • 2
  1. 1.Emergency DepartmentCentre Hospitalier Universitaire de Nantes, Hôtel-DieuNantesFrance
  2. 2.Faculté de Médecine and PharmacieUniversité de Nantes, EA 3826 Thérapeutiques Cliniques et Expérimentales des InfectionsNantesFrance
  3. 3.Faculté de Médecine and PharmacieUniversité de Nantes, EA 4275 SPHERE Biostatistics Pharmacoepidemiology and Human Science Research TeamNantesFrance
  4. 4.Department of Microbiology and Infection ControlCentre Hospitalier Universitaire de Nantes, Hôtel-DieuNantesFrance

Personalised recommendations